Stakeholder perspectives on the challenges surrounding management and supply of essential medicines
- 139 Downloads
Background Shortages of essential medicines impact patient safety and raise the costs of medicines to consumers and governments. Ongoing medicine shortages have become a critical issue that threaten global access to medicines. Objective The aim of this study was to explore key stakeholders’ perspectives on the challenges surrounding management and supply of essential medicines. Setting Western Pacific, Asia, Europe, North America, and Africa. Methods In-depth, semi-structured interviews with 47 participants were conducted across seven stakeholder groups globally. Stakeholders included government, academics, consumer groups, non-profit organisations, hospital healthcare providers, manufacturers, and wholesaler/distributors. A grounded theory approach was applied to qualitative analysis. Main outcome measure Stakeholders’ perspectives on the challenges surrounding management and supply of essential medicines. Results This study showed that supporting consumer demand for a wide range of therapeutic products required increased resources and coordination. Four main themes were identified: (1) consumer demand for a wide range of individual therapeutic needs cannot be sustained by the supply chain; (2) there lacked a coordinated approach to manage medicine shortages throughout the supply chain; (3) there were gaps in communication throughout the continuum of the supply chain; and (4) both international and local disruptions contributed to vulnerabilities in the supply chain. Conclusion Prioritisation of supply, logistics, and budget decisions around essential medicines need to be clearly coordinated between stakeholders to mitigate medicine shortages. Financial structures should include resilience planning to support fair and equitable access to medicines that meet consumer needs.
KeywordsAccess to medicines Drug shortages Formulary Medicine shortages Procurement Resilience Supply chain
We would like to acknowledge all the participants for their much appreciated time and support in this study. We would like to acknowledge affiliation with the World Hospital Pharmacy Research Consortium (WHoPReC).
Conflicts of interest
- 4.European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA good practice—reducing risk for drug products shortages. European Federation of Pharmaceutical Industries and Associations; 2013. Accessed 1 Aug 2018. https://www.fdanews.com/ext/resources/files/11/11-12-13-EFPIA.pdf.
- 5.United States Food and Drug Administration (FDA). Strategic plan for preventing and mitigating drug shortages; 2013, p. 7–8. Accessed on 1 Aug 2018. https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM372566.pdf.
- 6.FDA. Third annual report on drug shortages for calendar year 2015. Department of Health and Human Services Food and Drug Administration (FDA); 2015. Accessed on 1 Aug 2018. https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM488353.pdf.
- 7.FDA. FDA drug shortage report; 2011.Google Scholar
- 8.World Health Organization (WHO). The selection and use of essential medicines. Report of the WHO Expert Committee (including the 12th Model List of Essential Medicines). The World Health Organization; 2002, p. 1–41.Google Scholar
- 10.Cherici C, McGinnis P, Russell, W. Buyer beware: drug shortages and the gray market. Accessed on 1 Apr 2019. http://www.anco-online.org/GrayMarketAnalysis-Premier.pdf.
- 11.GaBI. UK drug shortages are far from being solved. Accessed on 1 Aug 2018. http://gabionline.net/Pharma-News/UK-drug-shortages-are-far-from-being-solved.
- 12.Schulman RD, Sweet G. Impact of drug shortages: results of two independent national surveys. 2011.Google Scholar
- 15.Koh R, Schuster EW, Chackrabarti I, et al. Securing the pharmaceutical supply chain. White Paper, Auto-ID Labs, Massachusetts Institute of Technology. 2003, pp. 1–19.Google Scholar
- 16.WHO. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000–2003. The World Health Organization; 2000, p. 1–81.Google Scholar
- 17.WHO. Equitable access to essential medicines: a framework for collective action. WHO policy perspectives on Medicines; 2004.Google Scholar
- 18.WHO. The WHO Model List of Essential Medicines, 19th edn. Geneva: The World Health Organization; 2015.Google Scholar
- 24.Duong MH. Exploring the essential medicines list concept. Faculty of Pharmacy. Sydney, Australia: The University of Sydney; 2015, p. 79. Accessed on 1 Aug 2018. https://ses.library.usyd.edu.au/handle/2123/15331.
- 29.Bazeley P. Qualitative data analysis: practical strategies. London: SAGE Publications; 2013.Google Scholar
- 30.Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. Thousand Oaks: SAGE Publications; 1998.Google Scholar
- 31.Miles MB, Huberman AM. An expanded sourcebook: qualitative data analysis. Thousand Oaks: SAGE Publications; 1994.Google Scholar
- 32.Patton MQ. Qualitative research and evaluation methods. Thousand Oaks: Sage Publications; 2002.Google Scholar
- 33.Creswell JW. Qualitative inquiry and research design: choosing among five approaches. Qualitative inquiry and research design: choosing among five approaches. United States of America: SAGE Publications; 2013, p. 179–211.Google Scholar
- 34.WorldBank. Data & Statistics—Country Groups. Accessed on 1 Aug 2018. http://econ.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20421402~menuPK:64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html.
- 35.WorldBank. Data: country and lending groups. Accessed on 1 Aug 2018. http://data.worldbank.org/about/country-and-lending-groups.
- 38.WHO. Executive Summary: The Selection and Use of Essential Medicines (2015). Report of the 20th WHO Expert Committee on the Selection and Use of Essential Medicines. WHO; 2015, p. 1–14.Google Scholar
- 39.PBS TPBS. Section 100-highly specialised drugs program. Accessed on 1 Aug 2018. http://www.pbs.gov.au/info/browse/section-100/s100-highly-specialised-drugs.
- 40.PBS TPBS. Other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS). Accessed on 1 Aug 2018. http://www.health.gov.au/lsdp.
- 41.Edwards DJ, Coppens DG, Prasad TL, et al. Access to hepatitis C medicines: improving access to essential innovative treatments. Access to Medicine Foundation; 2015, p. 1–22.Google Scholar
- 43.Knaul FM, Wong R, Arreola-Ornelas H, et al. Household catastrophic health expenditures: a comparative analysis of twelve Latin American and Caribbean Countries. Salud Publ Mexico. 2011;53(Suppl 2):s85–95.Google Scholar
- 46.Patel B, Pichardo RV. Improve formulary adherence through effective provider engagement. Formulary. 2012;47:400–1.Google Scholar
- 55.McBeath B. Supplier risk and compliance management in practice: part 1. Accessed on 1 Aug 2018. http://www.clresearch.com/research/detail.cfm?guid=FED1EA59-3048-79ED-9902-8BE204B4C3DB.
- 58.Duckett S, Breadon P, Ginnivan L, et al. Australia’s bad drug deal: high pharmaceutical prices. Carlton: Grattan Institute; 2013.Google Scholar